{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T14:19:46Z","timestamp":1773584386133,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"State Key Laboratory of Dampness Syndrome of Chinese Medicine","award":["SZ2020ZZ13"],"award-info":[{"award-number":["SZ2020ZZ13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hyperuricemia increases the risk of gout and cardiovascular complications, and how to manage asymptomatic hyperuricemia is controversial. Randomized controlled trials and comparative studies are needed to guide management and treatment. Studies show that Chinese medicine can decrease uric acid through multiple targets, but many of these studies have been conducted in animals because of the lack of a consistent prescription and mechanism. Therefore, we designed this research to study whether Chinese medicine is truly effective and which target is essential by using an approved prescription of a Fuling-Zexie decoction to further guide large sample experiments to determine whether Chinese medicine can reduce the long-term incidence of gout and cardiovascular events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This pilot study is a prospective, double-blinded, randomized, placebo-controlled clinical trial developed from March 2020 to December 2021. Thirty people with asymptomatic hyperuricemia will be recruited and assigned to either the Chinese medicine group or placebo group, and each group will have 15 subjects. During the 12-week observation period, there will be 4 visits. The decline in uric acid is the main outcome measure, and urinary uric acid, inflammatory biomarkers, and other indices that may be involved in lowering uric acid are the secondary outcome measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will probe the effect of Chinese medicine treatment on hyperuricemia and explore possible therapeutic mechanisms. By performing this trial, we hope to provide evidence and data to support further large clinical studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=61414\">ChiCTR2000038575<\/jats:ext-link>.\u00a0Registered on September 24, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06479-3","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:09:04Z","timestamp":1655723344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Jingyao","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaowen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"issue":"1","key":"6479_CR1","first-page":"27","volume":"58","author":"T Pascart","year":"2019","unstructured":"Pascart T, Liot\u00e9 F. Gout: state of the art after a decade of developments. Rheumatol (Oxford). 2019;58(1):27\u201344.","journal-title":"Rheumatol (Oxford)."},{"issue":"03","key":"6479_CR2","first-page":"235","volume":"56","author":"L Lin","year":"2017","unstructured":"Lin L, Xiao-xia Z, Dai Y, et al. Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases. Chin J Internal Med. 2017;56(03):235\u201348.","journal-title":"Chin J Internal Med"},{"key":"6479_CR3","volume":"2015","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. BioMed Res Int. 2015;2015:762820.","journal-title":"BioMed Res Int"},{"issue":"06","key":"6479_CR4","first-page":"462","volume":"36","author":"W Dan-chen","year":"2018","unstructured":"Dan-chen W, Yi-cong Y, Song-lin Y. Survey for variation of prevalence of hyperuricemia and its correlations with blood glucose and lipid in healthy adults receiv-ing physical examination at Peking Union Medical College Hospital from 2012 to 2017. Chin J Clin Lab Sci. 2018;36(06):462\u20136.","journal-title":"Chin J Clin Lab Sci"},{"issue":"2","key":"6479_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000585","volume":"31","author":"AM Abeles","year":"2019","unstructured":"Abeles AM, Pillinger MH. Gout and cardiovascular disease: crystallized confusion. Curr Opin Rheumatol. 2019;31(2):118\u201324.","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"6479_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026677","volume":"9","author":"Q Li","year":"2019","unstructured":"Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. https:\/\/doi.org\/10.1136\/bmjopen-2018-026677.","journal-title":"BMJ Open."},{"key":"6479_CR7","unstructured":"Li Changgui, Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin J Endocrinol Metab. 2020;36(1):1-13."},{"issue":"12","key":"6479_CR8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"key":"6479_CR9","doi-asserted-by":"crossref","unstructured":"Valsaraj R, Singh AK, Gangopadhyay KK, et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020;14(2):93-100.","DOI":"10.1016\/j.dsx.2020.01.007"},{"issue":"6","key":"6479_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"6479_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"6479_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/1756-185X.14266","volume":"25","author":"JPP Lorenzo","year":"2022","unstructured":"Lorenzo JPP, Sollano MHMZ, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(1):7\u201320.","journal-title":"Int J Rheum Dis."},{"issue":"8","key":"6479_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924\u20139.","journal-title":"J Investig Med."},{"issue":"17","key":"6479_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2169\/internalmedicine.54.4310","volume":"54","author":"P Liu","year":"2015","unstructured":"Liu P, Wang H, Zhang F, Chen Y, Wang D, Wang Y. The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study. Intern Med. 2015;54(17):2129\u201337.","journal-title":"Intern Med."},{"issue":"6","key":"6479_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945\u201350.","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"6479_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798\u2013810.","journal-title":"Am J Kidney Dis."},{"key":"6479_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijcard.2017.01.016","volume":"232","author":"Y Huang","year":"2017","unstructured":"Huang Y, Meng J, Sun B, et al. Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: a randomized, double-blind, placebo-controlled trial. Int J Cardiol. 2017;232:227\u201332.","journal-title":"Int J Cardiol."},{"issue":"21","key":"6479_CR18","first-page":"5248","volume":"45","author":"W Xing","year":"2020","unstructured":"Xing W, Ning X, Hong-lei L, et al. Study on mechanism of Fangji Huangqi Decoction on hypouricemic effect and renal protection in hyperuricemia mice. Chin J Chin Materia Medica. 2020;45(21):5248\u201355.","journal-title":"Chin J Chin Materia Medica"},{"issue":"1","key":"6479_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/13880209.2019.1568510","volume":"57","author":"C Fang","year":"2019","unstructured":"Fang C, Chen LY, He MZ, et al. Molecular mechanistic insight into the anti-hyperuricemic effect of Eucommia ulmoides in mice and rats [J]. Pharm Biol. 2019;57(1):112\u20139.","journal-title":"Pharm Biol"},{"issue":"07","key":"6479_CR20","first-page":"1449","volume":"38","author":"Z Jin-xiang","year":"2016","unstructured":"Jin-xiang Z, Bing-bing X, Juan W, et al. Hypouricemic effects of acteoside and isoacteoside from Plantaginis Semen on mice with acute hyperuricemia and their possible mechanisms. Chin Traditional Patent Med. 2016;38(07):1449\u201354.","journal-title":"Chin Traditional Patent Med"},{"key":"6479_CR21","unstructured":"Zhang Xiaoxi, Xing Mengyu, Zhao Xinyu,et al. Effect and mechanism of modified Sanmiao pill in the treatment of gouty arthritis through NLRP3 inflammasome axis and NF-\u03baB signaling pathway. J Zhejiang Chin Med Univ. 2019;43(10):1130-1137."},{"issue":"1","key":"6479_CR22","first-page":"83","volume":"32","author":"Z Yuan-yuan","year":"2020","unstructured":"Yuan-yuan Z, Zhong-nan L. Effect of biling prescription on PGE2 and COX-2 levels in diabetic gout model rats. J Jiangxi University TCM. 2020;32(1):83\u20136.","journal-title":"J Jiangxi University TCM"},{"issue":"7","key":"6479_CR23","first-page":"147","volume":"20","author":"Y Xue-fang","year":"2014","unstructured":"Xue-fang Y, Yong-chang W, Yong-dong Z, et al. Effect of different extracts from modified Siwu Siteng Decoction on acute gouty arthritis in rats. Chin J Experiment Traditional Med Formulae. 2014;20(7):147\u201351.","journal-title":"Chin J Experiment Traditional Med Formulae"},{"issue":"17","key":"6479_CR24","first-page":"76","volume":"52","author":"L Yan","year":"2014","unstructured":"Yan L, Zhanyuan L, Lifu X. Influence of Xuanbi decoction on serum high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-3(MMP-3) levels of patients with acute gouty arthritis. China Modern Doctor. 2014;52(17):76\u20138.","journal-title":"China Modern Doctor"},{"issue":"9","key":"6479_CR25","first-page":"129","volume":"21","author":"P Fan","year":"2015","unstructured":"Fan P, Chang T, Zhao YZ, et al. Experimental study of Bixie Chubi Tang in treating gout. Chin J Experiment Traditional Med Formulae. 2015;21(9):129\u201332.","journal-title":"Chin J Experiment Traditional Med Formulae"},{"issue":"12","key":"6479_CR26","first-page":"35","volume":"12","author":"Z Min","year":"2006","unstructured":"Min Z, Xiao-ming L, Wei Z, et al. The influences of Biqing Capsule on the uric acid metabolism in chicken model of hyperuricemia. Chin J Experiment Traditional Med Formulae. 2006;12(12):35\u20136.","journal-title":"Chin J Experiment Traditional Med Formulae"},{"key":"6479_CR27","doi-asserted-by":"publisher","first-page":"20602","DOI":"10.1038\/srep20602","volume":"6","author":"Z Guo","year":"2016","unstructured":"Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016;6:20602.","journal-title":"Sci Rep"},{"issue":"2","key":"6479_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12013-014-0253-5","volume":"71","author":"SC Xing","year":"2015","unstructured":"Xing SC, Meng DM, Chen Y, et al. Study on the diversity of Bacteroides and Clostridium in patients with primary gout. Cell Biochem Biophys. 2015;71(2):707\u201315.","journal-title":"Cell Biochem Biophys"},{"issue":"01","key":"6479_CR29","first-page":"177","volume":"46","author":"L Xing","year":"2021","unstructured":"Xing L, Fu-jiang C, Shi-lin J, et al. Preliminary study on effect of Phellinus igniarius ethanol extract on serum uric acid metabolism and gut microbiome in rats. China J Chin Materia Medica. 2021;46(01):177\u201382.","journal-title":"China J Chin Materia Medica"},{"issue":"02","key":"6479_CR30","first-page":"142","volume":"27","author":"S Ke-yu","year":"2011","unstructured":"Ke-yu S, Zhen-you J, Qun-chao Y, et al. Experimental study on the effect of Radixcodonopsis and Poria on intestinal flora in mice. Chin J Clin Pharmacol. 2011;27(02):142\u20135.","journal-title":"Chin J Clin Pharmacol"},{"key":"6479_CR31","unstructured":"Fan Bo, Huang Ying. An English-Chinese Chinese-English Glossary of Traditional Chinese Medicine. Shanghai foreign language education press, Shanghai China, 2008."},{"key":"6479_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ."},{"key":"6479_CR33","unstructured":"Zheng Xiao-yu, et al. The guiding principles for clinical Research of New Chinese medicines (trial). China Med Sci Press. 2002."},{"key":"6479_CR34","doi-asserted-by":"crossref","unstructured":"Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis.\u00a02020;79(1):31-38.","DOI":"10.1136\/annrheumdis-2019-215315"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06479-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:16:48Z","timestamp":1655723808000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06479-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6479"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06479-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (BF2020-172-01).All the subjects involved in the research will be informed of the objectives, duration, treatment, possible risks, rights and interests, etc. Investigators or designated representatives will obtain written informed consent from all participants. The study consent process includes permission to collect intestinal flora specimens for additional trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"517"}}